Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00204581
Status:
COMPLETED
Last Update Posted:
2011-08-19
First Post:
2005-09-13
Brief Title:
Intralesional Treatment With Interleukin-2 Proleukin in Soft Tissue Melanoma Metastases
Sponsor:
University Hospital Tuebingen
Organization:
University Hospital Tuebingen
Study Overview
Official Title:
Intralesional Treatment With Interleukin-2 Proleukin in Soft Tissue Melanoma Metastases A Phase II Prospective Open Multicenter Trial
Status:
COMPLETED
Status Verified Date:
2009-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The intra-perilesional application of interleukin-2 seems to be a safe and effective treatment of skin and soft tissue metastases in malignant melanoma Especially in case of intransit metastases the overall survival rate is still 20-30
However the management of intransit metastases is sometimes difficult because of frequent recurrences IL-2 intralesionally seems to be an non-invasive option as pilot studies indicate In this study the safety and efficacy of IL-2 are evaluated
However the management of intransit metastases is sometimes difficult because of frequent recurrences IL-2 intralesionally seems to be an non-invasive option as pilot studies indicate In this study the safety and efficacy of IL-2 are evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None